iSpecimen Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated revenue of $151,940 for the quarter, a stark decline of approximately 79% compared to $713,135 in the same period last year. For the first half of 2026, revenue totaled $307,949, down 83% from $1,770,645 in the first half of 2025. This decline was attributed to a substantial decrease in specimen count, which fell by about 87% from 2,533 specimens in Q2 2025 to 335 in Q2 2026.
The company's operating expenses also saw a notable reduction, decreasing by 40% to $1,514,926 in Q2 2026 from $2,534,561 in Q2 2025. This reduction was driven by lower costs in several areas, including a significant drop in cost of revenue, which fell by 81% to $83,290. However, sales and marketing expenses surged by 111% to $544,465, reflecting increased advertising efforts aimed at boosting revenue amidst declining sales. Despite these cost-cutting measures, iSpecimen reported a net loss of $1,362,811 for the quarter, compared to a loss of $1,047,243 in the prior year.
In terms of strategic developments, iSpecimen has been focusing on enhancing its technology platform, which includes the launch of an AI-powered Inventory Agent designed to streamline the procurement process. The company capitalized $700,000 in internally developed software costs during the first half of 2026, reflecting its commitment to improving operational efficiency. Additionally, the company executed a reverse stock split at a ratio of 1-for-40 in April 2026 to comply with Nasdaq listing requirements.
Operationally, iSpecimen's customer base has been affected by broader economic conditions, leading to a decrease in orders. The company reported a working capital deficit of $992,538 as of June 30, 2026, and a total cash position of $4,414,364, down from $6,880,835 at the end of 2025. The company has implemented measures to reduce costs, including workforce reductions that have led to a 67% decrease in monthly compensation costs since January 2024. However, technology costs increased by approximately 450% in the same period due to investments in software development.
Looking ahead, iSpecimen's management expressed uncertainty regarding its ability to continue as a going concern, citing the need for additional working capital and the challenges of generating sufficient revenue. The company is actively pursuing strategies to enhance revenue generation and manage expenses, but acknowledges that many factors influencing its success are beyond its control. The outlook remains cautious as the company navigates a challenging market environment while striving to stabilize its financial position.
About iSpecimen Inc.
iSpecimen Inc. operates a technology-driven marketplace connecting life science researchers with human biospecimens and associated data from healthcare providers worldwide. Its platform streamlines biospecimen procurement, offering access to diverse specimen types and extensive healthcare data, supporting research in diagnostics, therapeutics, and precision medicine. The company facilitates compliant, efficient transactions between researchers and biospecimen providers, enabling accelerated medical discovery and development.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov